Μαλαισία - Αγγλικά - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

imeks pharma sdn. bhd. - sulphasalazine -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

orphan australia pty ltd - mesalazine -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 3000 mg - granules, modified release - excipient ingredients: aspartame; carmellose sodium; microcrystalline cellulose; citric acid; hypromellose; magnesium stearate; methylcellulose; povidone; colloidal anhydrous silica; simethicone; sorbic acid; purified talc; titanium dioxide; triethyl citrate; methacrylic acid copolymer; flavour - salofalk granules granules are indicated in the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 1000 mg - suppository, moulded - excipient ingredients: hard fat - treatment of ulcerative proctitis

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 1500 mg - granules, modified release - excipient ingredients: sorbic acid; magnesium stearate; triethyl citrate; hypromellose; methylcellulose; aspartame; povidone; purified talc; microcrystalline cellulose; methacrylic acid copolymer; carmellose sodium; simethicone; citric acid; colloidal anhydrous silica; titanium dioxide; flavour - salofalk granules are indicated for the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 500 mg - tablet, enteric coated - excipient ingredients: sodium carbonate; glycine; povidone; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; calcium stearate; hypromellose; methacrylic acid copolymer; purified talc; titanium dioxide; iron oxide yellow; macrogol 6000; basic butylated methacrylate copolymer - salofalk granules and tablets are indicated in the treatment of acute ulcerative colitis of mild to moderate severity, and for the maintenance of remission and/or the long term treatment of ulcerative colitis. treatment of acute episodes and maintenance of remission of crohn's ileitis and colitis.

Καναδάς - Αγγλικά - Health Canada

avir pharma inc. - mesalazine - suppository - 1g - mesalazine 1g - anti-inflammatory agents

Καναδάς - Αγγλικά - Health Canada

avir pharma inc. - mesalazine - foam - 1g - mesalazine 1g - anti-inflammatory agents

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 1 g - foam - excipient ingredients: propane; cetostearyl alcohol; disodium edetate; propylene glycol; butane; polysorbate 60; isobutane; sodium metabisulfite - salofalk foam enemas are indicated in the treatment of acute ulcerative colitis of mild to moderate severity and for the maintenance treatment of ulcerative colitis.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - mesalazine, quantity: 2000 mg - enema - excipient ingredients: sodium benzoate; carbomer 934p; disodium edetate; potassium acetate; potassium metabisulfite; xanthan gum; purified water - salofalk enemas are indicated in the treatment of acute ulcerative colitis of mild to moderate severity and for the maintenance treatment of ulcerative colitis.